

6-2016-4268 | Novel Autotaxin Inhibitor Drug for the treatment of Cancer and Asthma (XIIPHONATE)  
[Reich Reuven](#), HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

## Background

As for today, an oral treatment to metastasis therapy is still an unmet challenge. We discovered a new approach to treat metastatic disease in that was verified in several preclinical models.

## Our Innovation

A new approach to treat metastatic disease has been developed and verified in several preclinical models. This oral treatment, a novel small molecule, acts extracellularly and thereby prevents the metastatic spread. The new molecule has been successfully tested for Asthma models and will be further studied for its efficiency at in-vivo models for cancer.

## Advantages

- The new compounds' activity is limited to the extracellular compartment, thus there is no intracellular activity (toxicity)
- The activity of the new compound lasts at least 48 h following single oral administration
- The compound has unique clinical potential as cancer and metastasis therapy.
- Molecules of the type of the new compound s are potent inhibitors of extracellular enzymes that support tumor and metastatic growth

## Technology

The novel compound targets zinc-dependent enzymes in the extracellular compartment involved in tumor dissemination:

- Autotaxin (ATX) which generates lysophosphatidic acid (LPA).
- Carbonic Anhydrases (CA) IX, XII which regulates extracellular pH
- Matrix metalloproteinase (MMP) which regulates ECM degradation

## Patent Status

Contact for more information:



Keren-Or Amar  
VP, Business Development, Healthcare

**Yissum Research Development Company of the Hebrew University of Jerusalem**

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem

P.O. Box 39135, Jerusalem 91390 Israel

Telephone: 972-2-658-6688, Fax: 972-2-658-6689